Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2423 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Gérard Greig und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ironwood Pharmaceuticals, Basel, Switzerland. Hauptthemen laut MEDLINE: Renal Insufficiency, Area Under Curve. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ironwood Pharmaceuticals, Incorporated.
Abstract (Originalsprache)
Renal impairment is a common complication in patients with short bowel syndrome with intestinal failure (SBS‐IF). Glucagon‐like peptide‐2 analogs, such as apraglutide, have been developed as a treatment option for SBS‐IF. This study assessed the potential for apraglutide overexposure in individuals with severely impaired renal function versus healthy volunteers with normal renal function. In this phase 1, open‐label, multicenter, nonrandomized, parallel‐group study, a single dose of apraglutide 5 mg was administered subcutaneously to individuals with severely impaired renal function (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ironwood Pharmaceuticals, Basel, Switzerland.
Förderung
- Ironwood Pharmaceuticals, Incorporated
Zitieren
APA
Greig, G., Youssef, N. N., & Bolognani, F. (2024). Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2423
Vancouver
Greig G, Youssef NN, Bolognani F. Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2423
BibTeX
@article{Greig2024,
author = {Greig, Gérard and Youssef, Nader N and Bolognani, Federico},
title = {Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2423}
}
EUVIMED